ABSTRACT
Congenital factor V (FV) deficiency is a bleeding disorder associated with mild to severe hemorrhagic symptoms and a prevalence in the general population of 1 in 1,000,000 in the homozygous form. Patients with FV deficiency and clinically significant manifestations (mainly involving mucosal tracts) show very low or unmeasurable plasma FV levels and are usually homozygous or compound heterozygous for mutations located in the FV gene (F5 ). Heterozygous carriers have approximately half-normal levels of FV and are usually asymptomatic. Replacement therapy for FV-deficient patients can only rely on administration of fresh-frozen plasma because specific FV concentrates are unavailable and FV is not present in cryoprecipitate or prothrombin complex concentrates. A total of 56 mutations have been published to date as being responsible for severe or moderately severe FV deficiency; more than two thirds of these are null mutations (mainly decreasing FV expression), with the remaining being missense mutations (usually impairing FV secretion). This article will provide a concise description of the FV protein and gene and will review the molecular, clinical, and therapeutic aspects of FV deficiency.
KEYWORDS
Factor V - factor V deficiency - mutational spectrum - clinical manifestations - treatment
REFERENCES
1
Mann K G, Kalafatis M.
Factor V: a combination of Dr Jekyll and Mr Hyde.
Blood.
2003;
101
20-30
2
Stormorken H.
The discovery of factor V: a tricky clotting factor.
J Thromb Haemost.
2003;
1
206-213
3
Mannucci P M, Duga S, Peyvandi F.
Recessively inherited coagulation disorders.
Blood.
2004;
104
1243-1252
4
Lak M, Sharifian R, Peyvandi F, Mannucci P M.
Symptoms of inherited factor V deficiency in 35 Iranian patients.
Br J Haematol.
1998;
103
1067-1069
5
Acharya S S, Coughlin A, Dimichele D M. North American Rare Bleeding Disorder Study Group .
Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias.
J Thromb Haemost.
2004;
2
248-256
6
Zhang B, Spreafico M, Zheng C et al..
Genotype-phenotype correlation in combined deficiency of factor V and factor VIII.
Blood.
2008;
111
5592-5600
7
Kent W J, Sugnet C W, Furey T S et al..
The human genome browser at UCSC.
Genome Res.
2002;
12
996-1006
8
Chiu H C, Schick P K, Colman R W.
Biosynthesis of factor V in isolated guinea pig megakaryocytes.
J Clin Invest.
1985;
75
339-346
9
Gewirtz A M, Keefer M, Doshi K, Annamalai A E, Chiu H C, Colman R W.
Biology of human megakaryocyte factor V.
Blood.
1986;
67
1639-1648
10
Giampaolo A, Vulcano F, Macioce G et al..
Factor-V expression in platelets from human megakaryocytic culture.
Br J Haematol.
2005;
128
108-111
11
Sun H, Yang T L, Yang A, Wang X, Ginsburg D.
The murine platelet and plasma factor V pools are biosynthetically distinct and sufficient for minimal hemostasis.
Blood.
2003;
102
2856-2861
12
Dall'Osso C, Guella I, Duga S et al..
Molecular characterization of three novel splicing mutations causing factor V deficiency and analysis of the F5 gene splicing pattern.
Haematologica.
2008;
93
1505-1513
13
Frischmeyer P A, Dietz H C.
Nonsense-mediated mRNA decay in health and disease.
Hum Mol Genet.
1999;
8
1893-1900
14
Lejeune F, Maquat L E.
Mechanistic links between nonsense-mediated mRNA decay and pre-mRNA splicing in mammalian cells.
Curr Opin Cell Biol.
2005;
17
309-315
15
Jenny R J, Pittman D D, Toole J J et al..
Complete cDNA and derived amino acid sequence of human factor V.
Proc Natl Acad Sci U S A.
1987;
84
4846-4850
16
Cripe L D, Moore K D, Kane W H.
Structure of the gene for human coagulation factor V.
Biochemistry.
1992;
31
3777-3785
17
Nicolaes G A, Dahlbäck B.
Factor V and thrombotic disease: description of a janus-faced protein.
Arterioscler Thromb Vasc Biol.
2002;
22
530-538
18
Xue J, Kalafatis M, Mann K G.
Determination of the disulfide bridges in factor Va light chain.
Biochemistry.
1993;
32
5917-5923
19
Xue J, Kalafatis M, Silveira J R, Kung C, Mann K G.
Determination of the disulfide bridges in factor Va heavy chain.
Biochemistry.
1994;
33
13109-13116
20
Kumar H PM, Besman M J, Lundblad R L, Jenny N S, Mann K G.
Carbohydrate analysis of plasma factor V and factor VIII.
Thromb Haemost.
1999;
(Suppl 82)
102a
21
Macedo-Ribeiro S, Bode W, Huber R et al..
Crystal structures of the membrane-binding C2 domain of human coagulation factor V.
Nature.
1999;
402
434-439
22
Adams T E, Hockin M F, Mann K G, Everse S J.
The crystal structure of activated protein C-inactivated bovine factor Va: implications for cofactor function.
Proc Natl Acad Sci U S A.
2004;
101
8918-8923
23
Stoilova-McPhie S, Parmenter C D, Segers K, Villoutreix B O, Nicolaes G A.
Defining the structure of membrane-bound human blood coagulation factor Va.
J Thromb Haemost.
2008;
6
76-82
24
Lee C J, Lin P, Chandrasekaran V et al..
Proposed structural models of human factor Va and prothrombinase.
J Thromb Haemost.
2008;
6
83-89
25
Asselta R, Tenchini M L, Duga S.
Inherited defects of coagulation factor V: the hemorrhagic side.
J Thromb Haemost.
2006;
4
26-34
26
Lunghi B, Scanavini D, Castoldi E et al..
The factor V Glu1608Lys mutation is recurrent in familial thrombophilia.
J Thromb Haemost.
2005;
3
2032-2038
27
Schrijver I, Hong D W, Mandle L et al..
High frequency of premature termination mutations in the factor V gene: three factor V deficiency case reports and a mutation review.
Thromb Haemost.
2005;
93
610-611
28
Asselta R, Dall'Osso C, Duga S, Spreafico M, Saxena R, Tenchini M L.
Coagulation factor V gene analysis in five Indian patients: identification of three novel small deletions.
Haematologica.
2006;
91
1724-1726
29
Kling S J, Griffee M, Flanders M M, Rodgers G M.
Factor V deficiency caused by a novel missense mutation, Ile417Thr, in the A2 domain.
J Thromb Haemost.
2006;
4
481-483
30
Traynis I, Jones C D, Gibb C B, Acharya S S, Zehnder J L.
First molecular characterization of a patient with combined factor V and factor VII deficiency.
Thromb Haemost.
2006;
95
1031-1032
31
Yamakage N, Ikejiri M, Okumura K et al..
A case of coagulation factor V deficiency caused by compound heterozygous mutations in the factor V gene.
Haemophilia.
2006;
12
172-178
32
Zheng W D, Liu Y H, Liu H F, Chen Z H, Wang Y.
[Identification of two novel mutations of human blood coagulation factor V gene in a Chinese family with congenital factor V deficiency].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi.
2006;
23
515-518
33
Cai X H, Wang X F, Ding Q L, Fu Q H, Wang H L.
Factor V C1149G and 5609-10INSCGTGGTT causing factor V deficiency: molecular characterization by in-vitro expression.
Thromb Haemost.
2007;
98
683-685
34
Caudill J S, Sood R, Zehnder J L, Pruthi R K, Steensma D P.
Severe coagulation factor V deficiency associated with an interstitial deletion of chromosome 1q.
J Thromb Haemost.
2007;
5
626-628
35
Jones C D, Yeung C, Negro F, Zehnder J L.
Molecular characterization and subcellular localization of Tyr478del: a pathogenic in-frame deletion in coagulation factor V.
J Thromb Haemost.
2007;
5
431-433
36
Shinozawa K, Amano K, Suzuki T et al..
Molecular characterization of 3 factor V mutations, R2174L, V1813M, and a 5-bp deletion, that cause factor V deficiency.
Int J Hematol.
2007;
86
407-413
37
Lunghi B, Pinotti M, Maestri I, Batorova A, Bernardi F.
Evaluation of factor V mRNA to define the residual factor V expression levels in severe factor V deficiency.
Haematologica.
2008;
93
477-478
38
Song J, Guella I, Kwon K Y et al..
A novel in-frame deletion in the factor V C1 domain associated with severe coagulation factor V deficiency in a Korean family.
Blood Coagul Fibrinolysis.
2009;
20
150-156
39
Vos H L.
An online database of mutations and polymorphisms in and around the coagulation factor V gene.
J Thromb Haemost.
2007;
5
185-188
40
Castoldi E, Lunghi B, Mingozzi F et al..
A missense mutation (Y1702C) in the coagulation factor V gene is a frequent cause of factor V deficiency in the Italian population.
Haematologica.
2001;
86
629-633
41
Scanavini D, Girelli D, Lunghi B et al..
Modulation of factor V levels in plasma by polymorphisms in the C2 domain.
Arterioscler Thromb Vasc Biol.
2004;
24
200-206
42
Vos H L.
Inherited defects of coagulation factor V: the thrombotic side.
J Thromb Haemost.
2006;
4
35-40
43
Yamazaki T, Nicolaes G A, Sørensen K W, Dahlbäck B.
Molecular basis of quantitative factor V deficiency associated with factor V R2 haplotype.
Blood.
2002;
100
2515-2521
44
Murray J M, Rand M D, Egan J O, Murphy S, Kim H C, Mann K G.
Factor V New Brunswick: Ala221-to-Val substitution results in reduced cofactor activity.
Blood.
1995;
86
1820-1827
45
Steen M, Miteva M, Villoutreix B O, Yamazaki T, Dahlbäck B, Factor V.
Factor V New Brunswick: Ala221Val associated with FV deficiency reproduced in vitro and functionally characterized.
Blood.
2003;
102
1316-1322
46
Monaldini L, Asselta R, Malcovati M, Tenchini M L, Duga S.
The DNA-pooling technique allowed for the identification of three novel mutations responsible for afibrinogenemia.
J Thromb Haemost.
2005;
3
2591-2593
47
Duckers C, Simioni P, Spiezia L et al..
Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.
Blood.
2008;
112
3615-3623
48 Adcock D M, Hoefner D M, Kottke-Marchant K, Marlar R A, Szamosi D I, Warunek D J. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays: Approved Guideline, Fifth Edition. Wayne, PA; Clinical Laboratory Standards Institute 2008 CLSI document H21–A5
49
Zürcher M, Sulzer I, Barizzi G, Lämmle B, Alberio L.
Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature.
Thromb Haemost.
2008;
99
416-426
50
Di Paola J, Nugent D, Young G.
Current therapy for rare factor deficiencies.
Haemophilia.
2001;
7(Suppl 1)
16-22
51
Bolton-Maggs P H, Perry D J, Chalmers E A et al..
The rare coagulation disorders—review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation.
Haemophilia.
2004;
10
593-628
52
Peyvandi F, Duga S, Akhavan S, Mannucci P M.
Rare coagulation deficiencies.
Haemophilia.
2002;
8
308-321
53
Salooja N, Martin P, Khair K, Liesner R, Hann I.
Severe factor V deficiency and neonatal intracranial haemorrhage: a case report.
Haemophilia.
2000;
6
44-46
54
Tarantino M D, Ross M P, Daniels T M, Nichols W L.
Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin.
J Pediatr Hematol Oncol.
1997;
19
226-231
55
Chediak J, Ashenhurst J B, Garlick I, Desser R K.
Successful management of bleeding in a patient with factor V inhibitor by platelet transfusions.
Blood.
1980;
56
835-841
56
Salooja N, Martin P, Khair K, Liesner R, Hann I.
Severe factor V deficiency and neonatal intracranial haemorrhage: a case report.
Haemophilia.
2000;
6
44-46
57
Altisent C, Lozano M, Sol E et al..
Dental extraction using rFVIIa in a patient with severe FV deficiency.
Haemophilia.
2000;
6
408
58
Divanon F, Hecquard C, Borel-Derlon A.
Experience with use of recombinant activated factor VII.
J Clin Pharm Ther.
2002;
27
133-138
59
González-Boullosa R, Ocampo-Martínez R, Alarcón-Martín M J, Suárez-Rodríguez M, Domínguez-Viguera L, González-Fajo G.
The use of activated recombinant coagulation factor VII during haemarthroses and synovectomy in a patient with congenital severe factor V deficiency.
Haemophilia.
2005;
11
167-170
60
Lee C A, Chi C, Pavord S R UK Haemophilia Centre Doctors' Organization et al.
The obstetric and gynaecological management of women with inherited bleeding disorders—review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization.
Haemophilia.
2006;
12
301-336
Dr. Rosanna AsseltaPh.D.
Department of Biology and Genetics for Medical Sciences, University of Milan
Via Viotti 3/5 - 20133 Milan, Italy
eMail: rosanna.asselta@unimi.it